Literature DB >> 10406282

Decrease in serum concentrations of Helicobacter pylori IgG antibodies during antituberculosis therapy: the possible eradication by rifampicin and streptomycin.

M Sanaka, Y Kuyama, M Yamanaka, M Iwasaki.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10406282     DOI： 10.1111/j.1572-0241.1999.1983a.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN： 0002-9270            Impact factor:   10.864


× No keyword cloud information.
  10 in total

1.  Efficacy and tolerability of rifampicin-based rescue therapy for Helicobacter pylori eradication failure in peptic ulcer disease.

Authors:  Vineet Ahuja; Vikram Bhatia; S Dattagupta; Akshay Raizada; Mahesh Prakash Sharma
Journal:  Dig Dis Sci       Date:  2005-04       Impact factor: 3.199

Review 2.  Third-line rescue therapy for Helicobacter pylori infection.

Authors:  Rossella Cianci; Massimo Montalto; Franco Pandolfi; Giovan-Battista Gasbarrini; Giovanni Cammarota
Journal:  World J Gastroenterol       Date:  2006-04-21       Impact factor: 5.742

3.  14C-urea breath test in patients undergoing anti-tuberculosis therapy.

Authors:  Sayed Amir Mirbagheri; Amir Ali Sohrabpour; Mehrdad Hasibi; Babak Moghimi; Mehdi Mohamadnejad
Journal:  World J Gastroenterol       Date:  2005-03-21       Impact factor: 5.742

4.  Reliability of urinary tests for antibody to Helicobacter pylori in patients with pulmonary tuberculosis.

Authors:  Takatsugu Yamamoto; Taro Ishii; Tomotaka Kawakami; Yoko Sase; Chiaki Horikawa; Nozomu Aoki; Masaki Sanaka; Yasushi Kuyama
Journal:  World J Gastroenterol       Date:  2005-01-21       Impact factor: 5.742

Review 5.  Pathogenesis of Helicobacter pylori infection.

Authors:  Johannes G Kusters; Arnoud H M van Vliet; Ernst J Kuipers
Journal:  Clin Microbiol Rev       Date:  2006-07       Impact factor: 26.132

6.  13[C]-urea breath test as a novel point-of-care biomarker for tuberculosis treatment and diagnosis.

Authors:  Mandeep S Jassal; Gueno G Nedeltchev; Jong-Hee Lee; Seong Won Choi; Viorel Atudorei; Zachary D Sharp; Vojo Deretic; Graham S Timmins; William R Bishai
Journal:  PLoS One       Date:  2010-08-27       Impact factor: 3.240

Review 7.  Effect of Helicobacter pylori and Helminth Coinfection on the Immune Response to Mycobacterium tuberculosis.

Authors:  Javier Andrés Bustamante-Rengifo; Miryam Astudillo-Hernández; María Del Pilar Crespo-Ortiz
Journal:  Curr Microbiol       Date:  2021-07-12       Impact factor: 2.188

Review 8.  Helicobacter pylori infection and respiratory diseases: a review.

Authors:  Anastasios Roussos; Nikiforos Philippou; Konstantinos I Gourgoulianis
Journal:  World J Gastroenterol       Date:  2003-01       Impact factor: 5.742

9.  Recombinant human lactoferrin enhances the efficacy of triple therapy in mice infected with Helicobacter pylori.

Authors:  Yuping Yuan; Qinyi Wu; Guoxiang Cheng; Xuefang Liu; Siguo Liu; Juan Luo; Aimin Zhang; Li Bian; Jianquan Chen; Jiajun Lv; Xiangqian Dong; Gang Yang; Yunzhen Zhu; Lanqing Ma
Journal:  Int J Mol Med       Date:  2015-06-17       Impact factor: 4.101

10.  Comparison between the two drug regimens of PPI+Amoxicillin+ Rifampicin and PPI+Amoxicillin+ Levofloxacin for the treatment of H. pylori infections resistant to the first line drug regimen among patients referred to Ilam clinics.

Authors:  Ghobad Abangah; Alireza Raughani; Parisa Asadollahi; Khairollah Asadollahi
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2019
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.